HomeInsightsPE

Jagsonpal Pharmaceuticals Ltd PE Ratio

Jagsonpal Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.1 Cr

Volume transacted

stocks purchased

3.0 K

stocks traded

Last Updated time: 04 Oct 15:30 PM

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

PE

50.5

Last updated: 04 Oct 15:30 PM

Key Highlights

  • The P/E Ratio of Jagsonpal Pharmaceuticals Ltd is 50.5 as of 04 Oct 15:30 PM.
  • The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 9.6 on March 2019 to 32.9 on March 2024 . This represents a CAGR of 22.79% over 6 years. .
  • The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 436.35 as of 04 Oct 15:30.
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 21.8. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 158.1. The PE Ratio of Textiles industry is 37.6. In 2024.

Historical P/E Ratio of Jagsonpal Pharmaceuticals Ltd

No data available

Company Fundamentals for Jagsonpal Pharmaceuticals Ltd

No data available

Image

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM

PRICE

436.35

2.15 (0.50%)

stock direction

Last updated: 04 Oct 15:30

Share price Over Time

1M

1Y

3Y

5Y

Monitoring Jagsonpal Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Share Price

Date
leftPriceleft
03 Oct 2024434.2
01 Oct 2024429.8
30 Sep 2024419.15
27 Sep 2024412.3
26 Sep 2024413.05
25 Sep 2024421.25
24 Sep 2024413.65
23 Sep 2024412
20 Sep 2024408.35
19 Sep 2024401.95

SWOT Analysis Of Jagsonpal Pharmaceuticals Ltd

Strength

2

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Jagsonpal Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Jagsonpal Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Jagsonpal Pharmaceuticals Ltd

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Jagsonpal Pharmaceuticals Ltd

No data available

* All values are in %

About Jagsonpal Pharmaceuticals Ltd

  • Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
  • The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
  • Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
  • It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
  • In 1994, the company has also promoted Aresco Financial Services, a new financial company.

Jagsonpal Pharmaceuticals Ltd News Hub

News

Jagsonpal Pharmaceuticals AGM scheduled

Jagsonpal Pharmaceuticals announced that the 45th Annual General Meeting (AGM) of the comp...

Read more

13 Aug 202414:22

News

Jagsonpal Pharmaceuticals declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

01 Aug 202411:06

News

Jagsonpal Pharmaceuticals completes acquisition of India and Bhutan biz of Yash Pharma

Jagsonpal Pharmaceuticals completed the acquisition of India & Bhutan business of Yash Pha...

Read more

31 May 202414:15

News

Board of Jagsonpal Pharmaceuticals recommends final dividend

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meet...

Read more

21 May 202409:56

News

Jagsonpal Pharmaceuticals Ltd leads losers in 'B' group

Pakka Ltd, IFGL Refractories Ltd, Mangalore Chemicals & Fertilizers Ltd and SBC Exports Lt...

Read more

05 Feb 202414:45

News

Jagsonpal Pharmaceuticals to declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on ...

Read more

27 Jan 202416:27

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for PE of Jagsonpal Pharmaceuticals Ltd

What is the current PE Ratio of Jagsonpal Pharmaceuticals Ltd?

The Current PE Ratio of Jagsonpal Pharmaceuticals Ltd is 50.49 as on 4 Oct 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 4 Oct 2024.

What was the PE Ratio of Jagsonpal Pharmaceuticals Ltd last year?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd was 28.42 last year, now the PE ratio is 50.49, showing a year-on-year growth of 77.7%.

What does the PE Ratio of Jagsonpal Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd is 50.49. This ratio indicates that investors are willing to pay 50.49 times the earnings per share for each share of Jagsonpal Pharmaceuticals Ltd.

What is the PE Ratio Growth of Jagsonpal Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Jagsonpal Pharmaceuticals Ltd grew by 77.7% whereas, the EPS ratio grew by 48.1.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*